Nuclear Medicine, Azienda Ospedaliero Universitaria Policlinico S.Orsola-Malpighi, Bologna, Italy.
Nuclear Medicine, Istituti Clinici Scientifici Maugeri SpA SB IRCCS, Pavia, Italy.
Future Oncol. 2018 May;14(11):1101-1115. doi: 10.2217/fon-2017-0446. Epub 2018 Jan 23.
A significant number of patients radically treated for prostate cancer (PCa) will develop prostate-specific antigen recurrence (27-53%). Localizing the anatomical site of relapse is critical, in order to achieve the optimal treatment management. To date the diagnostic accuracy of standard imaging is low. Several desirable features have been identified for the amino-acid-based PET agent, fluciclovine (F) including: long F half-life which allows more practical use in centers without a cyclotron onsite; acting as a substrate for amino acid transporters upregulated in PCa or associated with malignant phenotype; lacking of incorporation into protein; and limited urinary excretion. Fluciclovine (F) is currently approved both in USA and Europe with specific indication in adult men with suspected recurrent PCa based on elevated prostate-specific antigen following prior treatment.
相当数量经根治性治疗的前列腺癌（PCa）患者将出现前列腺特异性抗原（PSA）复发（27-53%）。明确复发的解剖部位至关重要，以便实现最佳的治疗管理。迄今为止，标准影像学的诊断准确性较低。对于基于氨基酸的 PET 示踪剂，氟[^18^F]脱氧葡萄糖（F），已经确定了一些理想的特征，包括：半衰期长，允许在没有回旋加速器的中心更实际地使用；作为在 PCa 中上调或与恶性表型相关的氨基酸转运体的底物；不掺入蛋白质；和有限的尿排泄。氟[^18^F]脱氧葡萄糖（F）目前在美国和欧洲均获得批准，其适应证为：先前治疗后 PSA 升高的疑似复发性 PCa 成年男性。
